Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

Taldefgrobep

Stage Phase 2Stale

Sponsor Biohaven Therapeutics Ltd.

Route injection

Sources

registry, as of 2026-03-20Stale

https://clinicaltrials.gov/study/NCT07281495

Taldefgrobep Alfa in Adults With Overweight and Obesity. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE2. Lead sponsor Biohaven Therapeutics Ltd.. Enrollment 150. Conditions Obesity; Overweight. This is a multicenter, randomized, double-blind, placebo-controlled, multiple dose study to evaluate the efficacy, safety, and tolerability of taldefgrobep alfa in adults with overweight and obesity, with an open-label extension.

ClinicalTrials.gov NCT07281495 protocol and results modules

Studies

Taldefgrobep Alfa in Adults With Overweight and Obesity

Registry NCT07281495

Phase Phase 2

Status Active, not recruiting

Enrollment 150

Start 2025-11-24

Taldefgrobep Alpha once weekly

Regimen once weekly

Weeks 4

Comparator placebo

Population Obesity; Overweight

Placebo once weekly

Regimen once weekly

Weeks 4

Population Obesity; Overweight

Taldefgrobep Alpha once every 4 weeks

Regimen every 4 weeks

Weeks 4

Comparator placebo

Population Obesity; Overweight

Placebo once every 4 weeks

Regimen every 4 weeks

Weeks 4

Population Obesity; Overweight